# US 2002/0173012 A1 · Process for the preparation of pharmaceutically acceptable salts of (R,S)-S-adenosyl-L-methionine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0173012 A1
- Document ID: US20020173012A1
- Status: Published application
- Kind: A1
- Application number: 10/142,876
- Filed: 2002-05-13
- Published: 2002-11-21
- Earliest claimed: 2000-05-25
- Assignees: Chementecno S.r.l.
- Inventors: Marco Berna; Lino Sivieri; Gianni Santambrogio; Ermanno Valoti
- Web page: https://patentgrep.com/patent/US20020173012A1

## CPC

- C07H 1/08: from natural products
- C07H 19/16: Purine radicals
- C12P 19/40: having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present invention relates to a process for the preparation of pharmaceutically acceptable salts of (SS,RS)-S-adenosyl-L-methionine and allows to obtain the salified (RS)-(+)-S-adenosyl-L-methionine diastereoisomer in amounts lower than or equal to 3% with respect to the salified (SS)-(+)-S-adenosyl-L-methionine diastereoisomer; the salts that can be obtained by the process of the invention keep their configuration stable in time.

## Claims

### Claim 1

A process for the preparation of pharmaceutically acceptable salts of (SS,RS)-SAMe, wherein the salified (RS)-(+)-SAMe diastereoisomer is present in amounts lower than or equal to 3% with respect to the salified (SS)-(+)-SAMe diastereoisomer, which, at a temperature of 0-12° C., comprises:
the purification of (SS,RS)-S-adenosyl-L-methionine from enriched yeast, which shall contain at least 6 g/l thereof, which comprises:
(a) the adjustment of the pH value to 1.2-3.5;
(b) the preparation of an aqueous lysate of (SS,RS)-SAMe from the enriched yeast;
(c) the microfiltration of the resulting lysate;
(d) the absorption of the resulting microfiltrate on a weak acid resin, by eluting with a 0.1-2 N inorganic acid solution;
(e) the decolouration of the resulting eluate;
the concentration of the decolourised eluate by reverse osmosis, from 30 to 70% by volume;
the addition of stoichiometric amounts of at least a pharmaceutically acceptable acid to the concentrated eluate, so as to obtain the corresponding pharmaceutically acceptable salt of (SS,RS)-SAMe.

### Claim 2 (depends on 1)

Process according to claim 1, wherein the pharmaceutically acceptable salt of (SS,RS)-SAMe is subjected to lyophilization.

### Claim 3 (depends on 1, 2)

Process according to claim 1 or 2, wherein the pH value in step (a) is 1-2.

### Claim 4

Process according to any of the preceding claims, wherein the preparation of the lysate in step (b) takes place by passing the yeast through a cell-breaking equipment.

### Claim 5

Process according to any of the preceding claims, wherein the temperature is 2-5° C.

### Claim 6

Process according to any of the preceding claims, wherein the enriched yeast contains at least 8-10 g/l of (SS,RS)-S-adenosyl-L-methionine.

### Claim 7

Process according to any of the preceding claims, wherein the pharmaceutically acceptable acid is selected from sulphuric acid and paratoluensulphonic acid.

### Claim 8

A pharmaceutically acceptable salt of (SS,RS)-S-adenosyl-L-methionine obtainable by the process according to any of the preceding claims.
